1152 DM001: A novel bispecific ADC targeting TROP2 and EGFR with potent anti-tumor efficacy in PDX models

• Yi Yang,
• Yuming Guo,
• W Frank An,
• Chaoshe Guo,
• Chengzhang Shang,
• Gao An,
• Zhuolin Li,
• Xuewa Guan

Affiliations

Yi Yang

1Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China

Yuming Guo

3Eucure (Beijing) Biopharma Co., Ltd., Beijing, China

W Frank An

1Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China

Chaoshe Guo

1Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China

Chengzhang Shang

1Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China

Gao An

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China

Zhuolin Li

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China

Xuewa Guan

2Doma Biopharmaceutical (Suzhou) Co., Ltd., Suzhou, Jiangsu, China